News and Trends 17 Aug 2022 Researchers invited to apply for DNA synthesized by Evonetix’s platform An early access program for semiconductor synthesized DNA has been opened by UK-based gene synthetic biology company, Evonetix. Evonetix’s DNA synthesis capability brings together semiconductor chip design and proprietary, thermally controlled synthesis chemistry, integral to the company’s future gene synthesis platforms. Silicon chip The company’s proprietary process utilizes a silicon chip to control the synthesis […] August 17, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 16 Aug 2022 Pneumagen embarks on phase 2 proof of concept influenza study Biotech company Pneumagen says the first person has been dosed in its phase 2 controlled human infection challenge study. Its product, Neumifil, is an intranasal, broad-spectrum antiviral treatment to prevent or, if infected, reduce and manage, viral respiratory tract infections. The phase 2 trial is a single center, randomized, double-blinded, placebo-controlled study evaluating two dose […] August 16, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 15 Aug 2022 Opthea secures up to $170M in financing for wet AMD treatment Opthea Limited, a clinical-stage biopharma company developing novel therapies to treat highly prevalent and progressive retinal diseases, has announced a non-dilutive financing transaction for up to US$170 million from investment funds working with Launch Therapeutics (Launch Tx) to finance and advance the ongoing phase 3 clinical trials and pre-commercialization activities of OPT-302 for wet age-related […] August 15, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 15 Aug 2022 Approval for Small Pharma major depressive disorder clinical trial Small Pharma Inc. has received approval from the U.K. Medicines and Healthcare products Regulatory Authority (MHRA) and the Regional Ethics Committee to initiate a drug interaction clinical trial in the U.K. The clinical trial will assess the interaction between serotonin reuptake inhibitors (SSRIs) and SPL026, the company’s lead N, N-dimethyltryptamine (DMT) candidate, in patients with […] August 15, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 11 Aug 2022 Acquisition of TeneoTwo and its clinical-stage T-cell engager completed AstraZeneca has said today (August 11) that it has completed its purchase of TeneoTwo including its B-cell non-Hodgkin lymphoma drug candidate. The company made an upfront payment of $100 million and then additional payments of up to $805 million contingent on research and development milestones as well as up to $360 million to TeneoTwo’s former […] August 11, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
Interview 10 Aug 2022 How the UK precision breeding bill could unshackle gene editing The U.K. is considering lowering restrictions on gene-edited crops. PacBio’s Neil Ward explains how the changes could impact the gene editing landscape. CRISPR gene editing technology has changed the game in the biotech industry by making it easier than ever before to make small changes to the genome. In addition to myriad healthcare applications, the […] August 10, 2022 - 6 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 10 Aug 2022 Research discovery may help diagnose and treat cancer and brain disorders Researchers at Queen’s University Belfast in Northern Ireland have revealed how the pathway of an identified protein could lead to early diagnosis and targeted treatment for several cancers and brain disorders. The team of researchers discovered how the journey or molecular pathway of an identified protein is both essential for brain development and how an […] August 10, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 Aug 2022 Start-up receives science and business support at Lab Hotel Stevenage Bioscience Catalyst (SBC) has welcomed Inspira Pharmaceuticals to its Lab Hotel, a facility offering free lab and office accommodation for six months to start-ups. The start-ups receive scientific and business support, access to SBC’s networks and introductions to investors to help their business grow and develop. Biotech start-up Rory McGoldrick, co-founder and CEO of […] August 9, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 4 Aug 2022 PolyPid to receive millions for commercialization of infection-fighting drug A drug to prevent surgical site infections (SSIs) in abdominal and cardiac surgeries in Europe is to be commercialized after two companies entered an exclusive licensing agreement. Israel-based PolyPid Ltd and UK-based ADVANZ PHARMA Corp. announced the agreement for lead drug candidate D-PLEX100 yesterday (August 3). Topline results Under the terms of the agreement, PolyPid will receive […] August 4, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 4 Aug 2022 New breast cancer treatment receives funding Researchers at Queen’s University Belfast in Northern Ireland have received funding from Breast Cancer Now to search for new treatments inspired by COVID-19 vaccine innovation. The research team will adapt lessons from the development of COVID-19 vaccines in the hunt for new treatments for an aggressive form of breast cancer. Niamh Buckley and Helen McCarthy […] August 4, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 3 Aug 2022 The biggest European biotech investments in July 2022 The mRNA firm Normax Biomed snagged Europe’s biggest private biotech investment in July 2022, with runners-up including AgomAb and Tropic Biosciences. Life sciences manufacturing companies saw a big windfall in Europe in July 2022 as the Cork-based Normax Biomed bagged around $301 million. The firm is establishing modular manufacturing facilities that could provide mRNA vaccines […] August 3, 2022 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 2 Aug 2022 Sosei Heptares and AbbVie enter second collaboration targeting neurological diseases A new drug discovery collaboration has taken place between Japanese Sosei Group Corporation and UK-based Abbvie with the hope of targeting neurological disease. This is the second partnership between the companies and offers the option to license agreement which is aimed at discovering, developing and commercializing small molecules that modulate novel G protein-coupled receptor (GPCR) […] August 2, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email